GLP-1 Medications and Eczema: What Emerging Research on Atopic Dermatitis Shows

Emerging research on GLP-1 medications and eczema suggests these metabolic drugs may influence atopic dermatitis through anti-inflammatory pathways that go well beyond their effects on blood sugar and weight.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. Clinical research cited here was conducted using FDA-approved pharmaceutical formulations unless otherwise noted. If you have atopic dermatitis, eczema, or any skin condition, consult your dermatologist or prescribing physician before starting, stopping, or adjusting any medication or treatment program. Individual results vary. All prescribing at Prescriva is performed by independently licensed healthcare providers.*

---

If you live with atopic dermatitis, also called eczema, you know it is not a simple skin problem. It is a chronic immune condition that flares unpredictably, disrupts sleep, and often does not respond the way you expect to standard treatments. Managing it requires attention to both what is happening at the skin surface and what is driving inflammation throughout the body.

That systemic dimension is why researchers are now paying attention to GLP-1 receptor agonists - medications like semaglutide and tirzepatide - as a potential influence on atopic dermatitis. These medications were developed for type 2 diabetes and weight management, but their effects on immune signaling and systemic inflammation are drawing increasing interest from dermatologists.

The research is still early. But a meaningful body of clinical and mechanistic evidence has accumulated in the past two years, and it is worth understanding what it shows and where its limits are.

---

What Is Atopic Dermatitis?

Atopic dermatitis is a chronic inflammatory skin condition characterized by itching, redness, skin barrier dysfunction, and episodic flares. It is the most common inflammatory skin disease globally, affecting an estimated 10 to 15 percent of children and 5 to 10 percent of adults. In the United States, roughly 16 million adults are living with the condition.

The underlying immune pathology is well characterized. Atopic dermatitis involves a skewed immune response driven by Th2 lymphocytes, cells that promote the production of cytokines including interleukin-4 (IL-4), interleukin-13 (IL-13), and immunoglobulin E (IgE). This Th2 overactivity disrupts the skin barrier, leaving skin more permeable to allergens and irritants, and perpetuates the itch-scratch cycle that defines the condition.

Atopic dermatitis does not exist in isolation. It sits at one end of what allergists call the atopic march: a progression through atopic dermatitis in infancy, followed by food allergies, allergic rhinitis, and asthma. And like many chronic inflammatory conditions, it clusters with metabolic dysfunction. People with obesity have meaningfully higher rates of atopic dermatitis than the general population, and the association appears to be bidirectional.

---

The Obesity-Eczema Connection

Understanding why obesity and atopic dermatitis co-occur helps explain why GLP-1 medications have come under scrutiny for their potential skin effects.

A 2025 systematic review published in the *International Journal of Molecular Sciences* examined the evidence linking atopic dermatitis with systemic metabolic disturbances [1]. The review found that adipose tissue in people with obesity secretes elevated levels of pro-inflammatory adipokines, including leptin and resistin, which can push the immune system toward the Th2 skew that drives atopic dermatitis. Additionally, obesity is associated with elevated systemic levels of IL-4 and IL-13, precisely the cytokines that dupilumab (Dupixent), the current first-line biologic for atopic dermatitis, is designed to block.

The review also found that higher body mass index is associated with greater atopic dermatitis severity, more frequent flares, and poorer response to standard topical treatments. This suggests weight-related inflammation is not just a coincidence of the condition but may be actively amplifying it.

This metabolic amplification creates a potential intervention point. If weight reduction can reduce adipokine-driven inflammation, and if GLP-1 medications have direct anti-inflammatory effects of their own, patients with atopic dermatitis and obesity may represent a population where the benefits could be additive.

---

How GLP-1 Medications May Influence Atopic Dermatitis

GLP-1 receptor agonists were designed to act on the pancreas and gut, but GLP-1 receptors are expressed on multiple cell types throughout the body, including keratinocytes (the primary cells of the outer skin layer) and several classes of immune cells involved in allergic inflammation [2].

A 2026 review published in *Pharmaceutics* analyzed the immunometabolic mechanisms by which GLP-1 receptor agonists may affect chronic inflammatory skin diseases, including atopic dermatitis [3]. The review identified several relevant pathways:

Cytokine modulation. GLP-1 receptor activation appears to reduce production of TNF-alpha, IL-6, and to some degree the Th2-promoting cytokines that drive atopic dermatitis. These reductions have been observed both in cell studies and in bloodwork from patients on GLP-1 medications.

NF-kB suppression. GLP-1 agonists can inhibit the NF-kB signaling pathway, a central driver of inflammatory gene expression. NF-kB is active in the skin of atopic dermatitis patients, and its suppression by GLP-1 receptor activation could reduce the inflammatory cascade that perpetuates flares.

Keratinocyte effects. GLP-1 receptors are expressed on keratinocytes, and activation of these receptors has been shown to modulate keratinocyte proliferation and inflammatory signaling. A separately published companion review in the *Journal of the American Academy of Dermatology* (JAAD) characterized these dermal mechanisms in detail [4].

Indirect effects via weight loss. When GLP-1 medications produce significant weight loss, they also reduce adipose tissue, which in turn reduces the production of pro-inflammatory adipokines described above. This indirect pathway may contribute meaningfully to skin improvement in overweight or obese patients with atopic dermatitis.

These are mechanisms, not confirmed treatment pathways. But they provide a plausible biological rationale for why GLP-1 medications might influence atopic dermatitis severity.

---

What Clinical Research Shows

The most directly relevant clinical evidence comes from a 2026 retrospective cohort study published in the *Journal of the American Academy of Dermatology* [5]. Researchers examined data from a large patient database, comparing rates and severity of atopic dermatitis in obese patients who were using GLP-1 receptor agonists against those who were not.

The study found that GLP-1 agonist use was associated with a lower rate of atopic dermatitis diagnoses and reduced prescribing of atopic dermatitis medications in the treated cohort compared to matched controls. The association held after adjustment for BMI, diabetes status, and other confounders, suggesting the effect was not simply explained by weight loss alone.

This is retrospective and observational evidence. It cannot prove that GLP-1 medications caused the atopic dermatitis improvement, and it cannot rule out selection bias or unmeasured confounders. But it is the kind of real-world signal that typically leads to prospective trials.

A complementary 2026 review in the *JAAD* covering clinical evidence and safety for GLP-1 receptor agonists in dermatology identified atopic dermatitis alongside psoriasis and hidradenitis suppurativa as skin conditions with credible mechanistic rationale and early clinical signals worth monitoring [6]. The review concluded that GLP-1 medications are not dermatological treatments but that their dermatological effects deserve investigation and clinical awareness.

---

Cardiovascular Risk in Atopic Dermatitis Patients: An Added Benefit

One finding from the GLP-1 and atopic dermatitis literature may have implications that extend beyond skin health. Atopic dermatitis is associated with elevated cardiovascular risk, particularly in patients with moderate to severe disease. Chronic systemic inflammation drives this risk in much the same way it drives cardiovascular disease in other inflammatory conditions.

A 2025 study published in the *Journal of the American Academy of Dermatology* examined whether GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes [7]. The study found that GLP-1 agonist use was associated with significantly reduced rates of cardiovascular events in this population, consistent with the cardiovascular benefits already established in the SELECT and LEADER trials for GLP-1 medications more broadly.

For patients managing both atopic dermatitis and metabolic risk factors, this cardiovascular profile adds another dimension to the conversation about GLP-1 medications.

---

Important Limitations

Before drawing conclusions, several limitations in the current evidence base deserve attention.

No Phase 3 trials for atopic dermatitis. There are no completed randomized controlled trials specifically designed to study GLP-1 medications as a treatment for atopic dermatitis. The clinical evidence that exists comes from observational data, retrospective analyses, and case reports. This is exploratory science, not clinical guidance.

Confounding from weight loss. In studies of obese patients with atopic dermatitis, it is difficult to separate the direct anti-inflammatory effects of GLP-1 medications from the indirect benefits of weight reduction. Both may contribute to any skin improvement observed.

Concurrent treatments. Many patients in observational studies are using topical corticosteroids, antihistamines, or biologics alongside any GLP-1 medication. Isolating the contribution of the GLP-1 medication to skin outcomes is methodologically complex.

GLP-1 medications are not dermatological treatments. They are indicated for type 2 diabetes and chronic weight management. Using them specifically for atopic dermatitis would be off-label, and no regulatory body has approved this use. Patients with atopic dermatitis should not interpret this research as a recommendation to seek GLP-1 medications for their skin condition.

---

What to Discuss With Your Healthcare Provider

If you have atopic dermatitis and also have obesity, metabolic syndrome, or type 2 diabetes, you may already be a candidate for GLP-1 therapy for your metabolic conditions. In that context, there are a few things worth discussing with your care team:

Let your dermatologist know you are starting a GLP-1 medication. If you begin GLP-1 therapy for weight management or diabetes and subsequently notice changes in your atopic dermatitis, your dermatologist will benefit from knowing you started a new medication. Documenting baseline severity before starting is useful if changes occur.

Do not adjust or stop atopic dermatitis treatments without guidance. There is no current evidence that GLP-1 medications can replace established atopic dermatitis therapies such as topical corticosteroids, calcineurin inhibitors, or dupilumab. These treatments have proven efficacy, and any changes to your atopic dermatitis regimen should involve your dermatologist.

Discuss the metabolic connection. If you have severe atopic dermatitis and have not yet been evaluated for obesity-related metabolic factors, this may be worth raising. Managing weight and metabolic inflammation may have meaningful effects on atopic dermatitis severity, independent of any specific GLP-1 effect.

---

Key Takeaways

Research into GLP-1 medications and eczema is still in its early stages, but the mechanistic rationale and initial clinical signals are genuine and worth following.

What the current evidence supports:

• Atopic dermatitis and obesity share inflammatory pathways, including elevated Th2 cytokines and adipokine-driven inflammation, that GLP-1 medications may influence [1, 3]
• GLP-1 receptors are expressed on keratinocytes and immune cells, suggesting direct skin-level mechanisms beyond weight loss alone [2, 4]
• A retrospective cohort study found GLP-1 agonist use was associated with lower rates of atopic dermatitis diagnoses and reduced medication use in obese patients [5]
• Dermatology-focused clinical reviews have flagged atopic dermatitis as a condition warranting prospective study of GLP-1 effects [6]
• GLP-1 medications appear to reduce cardiovascular risk in patients with atopic dermatitis and type 2 diabetes, adding a metabolic benefit relevant to this population [7]

No Phase 3 trials in atopic dermatitis patients have been completed, and GLP-1 medications are not treatments for eczema. All research cited here involved FDA-approved semaglutide, liraglutide, or tirzepatide formulations; these findings cannot be applied directly to compounded versions, which have not undergone clinical trials.

If you have atopic dermatitis alongside obesity or metabolic conditions, speaking with both your dermatologist and a weight management provider is the appropriate starting point.

*This is not medical advice. Consult your healthcare provider before making any changes to your medications or treatment plan.*

---

References

1. Matwiejuk M, et al. Is Atopic Dermatitis Associated with Systemic Metabolic Disturbances? A Systematic Review. *Int J Mol Sci.* 2025 Jun 19. PMID 40565347
2. Žaliukaitė G, et al. Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes. *J Clin Med.* 2026 Apr 13. PMID 42074746
3. Andrzejczak K, et al. GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives. *Pharmaceutics.* 2026 May 15. PMID 42198298
4. Narla S, et al. JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health. *J Am Acad Dermatol.* 2026 Feb 16. PMID 41707707
5. Burke SM, et al. Association of glucagon-like peptide-1 agonist use with atopic dermatitis in obese patients: A retrospective cohort study. *J Am Acad Dermatol.* 2026 Feb. PMID 41033491
6. Narla S, et al. JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology. *J Am Acad Dermatol.* 2026 Feb 14. PMID 41698604
7. Braun N, et al. Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes. *J Am Acad Dermatol.* 2025 Dec. PMID 40835131